https://www.prognyx.com/blog/amgen-s-imdelltra-plus-imfinzi-cuts-death-risk-58-in-first-line-es-sclcPrognyxen2026-10-24Amgen's Imdelltra plus Imfinzi cuts death risk 58% in first-line ES-SCLC https://www.prognyx.com/blog/innovent-s-arcotatug-tavatecan-clears-os-and-pfs-in-phase-3-gastric-cancer-at-esPrognyxen2026-10-23Innovent's arcotatug tavatecan clears OS and PFS in Phase 3 gastric cancer at ESMO